| Healthcare utilization and costs associated with treatment for opioid dependence A Shah, M Duncan, N Atreja, KS Tai, M Gore Journal of medical economics 21 (4), 406-415, 2018 | 15 | 2018 |
| Disease burden following non-cardioembolic minor ischemic stroke or high-risk TIA: a GWTG-Stroke study BG Kaufman, S Shah, AS Hellkamp, BL Lytle, GC Fonarow, LH Schwamm, ... Journal of Stroke and Cerebrovascular Diseases 29 (12), 105399, 2020 | 13 | 2020 |
| Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases GYH Lip, A Keshishian, A Kang, X Luo, N Atreja, Y Zhang, P Schuler, ... Journal of Thrombosis and Thrombolysis 54 (1), 33-46, 2022 | 9 | 2022 |
| New heart failure after myocardial infarction (from the National Cardiovascular Data Registries [NCDR] linked with all-payer claims) KF Faridi, N Bhalla, N Atreja, J Venditto, ND Khan, T Wilson, E Fonseca, ... The American Journal of Cardiology 151, 70-77, 2021 | 8 | 2021 |
| Copayment reduction voucher utilization and associations with medication persistence and clinical outcomes: findings from the ARTEMIS trial AC Fanaroff, ED Peterson, LA Kaltenbach, KJ Anstrom, GC Fonarow, ... Circulation: Cardiovascular Quality and Outcomes 13 (5), e006182, 2020 | 8 | 2020 |
| Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and multimorbidity AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, C Gutierrez, ... Advances in Therapy 40 (3), 887-902, 2023 | 6 | 2023 |
| Patients' beliefs regarding counseling provided by community pharmacists: an application of the theory of planned behavior ML Fleming, EA Ferries, MD Hatfield, N Atreja, A Yucel, PP Rane, ... Journal of Pharmaceutical Health Services Research 6 (1), 77-79, 2015 | 5 | 2015 |
| Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study S Deitelzweig, A Keshishian, A Kang, A Jenkins, N Atreja, P Schuler, ... European Journal of Internal Medicine 108, 37-42, 2023 | 3 | 2023 |
| Payer formulary exclusions of apixaban: how patients respond and potential implications S Deitelzweig, E Terasawa, A Kang, N Atreja, DM Hines, A Noman, X Luo Current Medical Research and Opinion 38 (11), 1885-1890, 2022 | 3 | 2022 |
| Hospitalization for myocardial infarction with ticagrelor or clopidogrel in patients with acute coronary syndrome: an on-treatment comparative effectiveness analysis T Olufade, N Atreja, N Bhalla, J Venditto, D Bhandary, K Chafekar, ... Cardiology and Therapy 10, 515-529, 2021 | 2 | 2021 |
| Translating Clinical Evidence Into Value-Based Payment Models: Pooled Analyses of Innovative Real-World Outcomes Agreements for Ticagrelor in the United States D Bhandary, N Atreja, DA Belletti, N Bhalla, ND Khan, DS Cobden American Journal of Managed Care 26 (13), S275-S286, 2020 | 2 | 2020 |
| A real-world evaluation of primary medication nonadherence in patients with nonvalvular atrial fibrillation prescribed oral anticoagulants in the United States I Hernandez, V Divino, L Xie, DW Hood, M DeKoven, W Kariuki, G Bell, ... American Journal of Cardiovascular Drugs 23 (5), 559-572, 2023 | 1 | 2023 |
| Payer formulary tier increases of apixaban: how patients respond and potential implications S Deitelzweig, E Terasawa, N Atreja, A Kang, DM Hines, AD Dhamane, ... Current Medical Research and Opinion 39 (8), 1093-1101, 2023 | 1 | 2023 |
| PCN101 INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER: ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND PROJECT (HCUP) DATA B Patel, KM Kamal, N Atreja Value in Health 3 (13), A43, 2010 | 1 | 2010 |
| Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample BD Horne, N Atreja, J Venditto, T Wilson, JB Muhlestein, JR St. Clair, ... Journal of Clinical Medicine 13 (10), 2844, 2024 | | 2024 |
| Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims GYH Lip, V Noxon, A Kang, X Luo, N Atreja, S Han, D Cheng, J Jiang, ... Journal of Thrombosis and Thrombolysis, 1-11, 2024 | | 2024 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OUTCOMES AMONG MEDICARE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WHO SWITCHED FROM WARFARIN TO DIRECT ORAL ANTICOAGULANTS N Atreja, V Noxon, A Kang, D Hines, J Jiang, M Hagan, D Cheng, ... Journal of the American College of Cardiology 83 (13_Supplement), 1242-1242, 2024 | | 2024 |
| Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation S Deitelzweig, A Kang, J Jiang, C Gao, X Luo, N Atreja, S Han, D Cheng, ... Journal of clinical medicine 13 (4), 1073, 2024 | | 2024 |
| The Association between Direct Oral Anticoagulants Prescribing Behavior and Non-Valvular Atrial Fibrillation Outcomes: An Instrumental Variable Analysis of Real-World Data N Atreja, SG Severtson, J Jiang, C Gao, DM Hines, D Cheng, M Hagan, ... Journal of Clinical Medicine 12 (22), 7190, 2023 | | 2023 |
| Geographic and Racial Variation in Oral Anticoagulant Treatment Among Commercially Insured Patients With Non-Valvular Atrial Fibrillation in the United States BD Atwater, R Singh, S Parmar, A Ogbonnaya, A Kang, C Russ, D Cheng, ... Circulation 148 (Suppl_1), A14004-A14004, 2023 | | 2023 |
